CONCORDBIONSEConcord Biotech LimitedLowNeutral
Announced Mon, 18 May · 17:31 IST

Sudhir Vaid has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Promoter Below 50pctOwnership Changes View source PDF

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.1%1-day move
₹1127.20
prior close
₹1127.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.8+1.4+1.4+1.2-1.1-0.6+2.0+0.3+0.8-6.8+17.1+16.7+18.5
Up moveDown movePending
AI summary

Promoter Sudhir Vaid, on behalf of all promoters, promoter group, and persons acting in concert (PAC), has disclosed holding 4,61,16,608 equity shares (44.08%) in Concord Biotech Limited as of March 31, 2026. The disclosure is filed under SEBI Regulation 31(4), which requires promoters to declare their shareholding and encumbrances annually. The promoter group explicitly confirms that no shares were encumbered — meaning no pledges, liens, or charges were placed on their shares — during the financial year ended March 31, 2026. The holding percentage of 44.08% places the promoter stake just below the 50% threshold. The disclosure was submitted on April 2, 2026.

Likely market impact

With promoters holding just under 45%, the company has significant public float. The explicit confirmation of zero encumbrance is a positive signal, indicating promoters have not pledged shares to raise debt — a concern for minority shareholders in some biotech companies.